| 04/23/2026 5:02 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/17/2026 2:01 PM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/13/2026 5:27 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/13/2026 5:17 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/10/2026 7:30 AM | Innate Pharma (1598599) Subject NOVO NORDISK A S (353278) Filed by | Form SCHEDULE 13G/A | |
| 04/08/2026 5:16 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/03/2026 6:02 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/02/2026 5:01 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 5:08 AM | Innate Pharma (1598599) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/26/2026 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/19/2026 6:11 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for IPHA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/18/2026 5:17 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:48 AM | ASTRAZENECA PLC (901832) Filed by ASTRAZENECA PLC (901832) Filed by Innate Pharma (1598599) Subject | Form SCHEDULE 13D/A | |
| 01/07/2026 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 5:08 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/11/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/28/2025 8:07 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2025 5:02 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/13/2025 5:02 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/10/2025 5:16 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/05/2025 5:06 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 7:00 AM | Innate Pharma (1598599) Subject NOVO NORDISK A S (353278) Filed by | Form SCHEDULE 13G/A | |
| 10/15/2025 5:15 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/17/2025 5:40 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/17/2025 5:24 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/15/2025 5:00 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 5:06 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/02/2025 7:52 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/04/2025 5:49 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/29/2025 5:24 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/07/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2025 5:05 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/13/2025 5:00 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/30/2025 7:31 AM | Innate Pharma (1598599) Subject NOVO NORDISK A S (353278) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/27/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/23/2025 5:11 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/23/2025 5:17 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/19/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/15/2025 5:00 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/13/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/12/2025 5:03 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
| 05/06/2025 5:01 AM | Innate Pharma (1598599) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |